Quick Answer
Yes, Synvisc-One denials are common, especially from commercial insurers and Medicare Advantage plans that require prior authorization or strict step-therapy documentation. The good news: many Synvisc-One denials are overturned on appeal when you provide complete documentation. This guide walks you through exactly how to do it.
Why Synvisc-One Injections Get Denied
Synvisc-One (hylan G-F 20) is a single-injection viscosupplement made by Sanofi. Because it is one of the higher-cost HA products and requires only one injection per treatment cycle, insurers sometimes scrutinize claims more closely than multi-injection alternatives.
1. Medical Necessity Not Established
Your insurer determined that Synvisc-One was not medically necessary based on the documentation submitted. This usually means the medical records did not clearly show that your knee osteoarthritis is severe enough to warrant viscosupplementation, or that the expected benefit was not adequately explained.
2. Conservative Treatment Failure Not Documented
Most plans require proof that you tried and failed at least 3 months of conservative treatment before approving HA injections. This typically includes physical therapy, oral NSAIDs or acetaminophen, activity modification, and sometimes cortisone injections. If your records do not include specific dates, dosages, and outcomes for these treatments, your claim may be denied.
3. Prior Authorization Not Obtained
Many commercial insurers and Medicare Advantage plans require prior authorization for Synvisc-One. If treatment was administered without PA approval, the claim will almost certainly be denied. Original Medicare generally does not require PA, but Medicare Advantage plans often do.
4. Injection Frequency Limits Exceeded
Most insurers allow one HA injection series per knee every 6 months. If your last Synvisc-One injection was less than 6 months ago, the new claim may be denied. Some plans impose 12-month intervals.
5. LCD Policy Requirements Not Met
Medicare coverage for viscosupplementation is governed by Local Coverage Determinations (LCDs) issued by Medicare Administrative Contractors. Each LCD has specific criteria regarding diagnosis codes, imaging requirements, and treatment history. If your claim does not align with the applicable LCD, it will be denied.
Synvisc-One Specific Note
Because Synvisc-One uses hylan G-F 20 (a chemically cross-linked form of hyaluronan with higher molecular weight), some insurers classify it differently from standard HA products. Make sure your provider uses the correct J-code (J7325) rather than a generic HA code.
Step-by-Step Appeal Process
Step 1: Review Your Denial Letter
Read your denial letter carefully and identify the specific reason listed. Common language includes “not medically necessary,” “criteria not met,” or “documentation insufficient.” Note the appeal deadline printed on the letter, as this is a strict cutoff. Call the number on your denial letter to request the plan’s coverage policy for viscosupplementation if it was not included.
Step 2: Gather Supporting Documentation
Collect these records from your provider’s office:
- Imaging reports: X-rays showing knee osteoarthritis (joint space narrowing, osteophytes, bone-on-bone changes)
- Conservative treatment records: Physical therapy notes with dates and session counts, prescription and OTC medication history with dosages and duration, cortisone injection dates and outcomes
- Functional assessment: WOMAC scores, VAS pain scale, or provider notes describing how knee pain affects walking, stairs, sleep, and daily activities
- Prior injection history: If you have had previous Synvisc-One or other HA injections, include dates and duration of relief to support retreatment
Step 3: Write Your Appeal Letter
Your appeal should be a combination of a personal statement and a provider letter of medical necessity. See the sample template below. Key points to address:
- Directly respond to each denial reason
- Reference specific dates of conservative treatments
- Cite your diagnosis codes and imaging findings
- Explain how knee pain limits your daily function
- Reference clinical evidence supporting Synvisc-One
Step 4: Submit and Follow Up
Submit your appeal package through your plan’s preferred method (online portal, fax, or certified mail). Keep copies of everything. Call 5 business days after submission to confirm receipt and ask for a timeline. Follow up weekly until you receive a decision.
Step 5: External Review Options
If your internal appeal is denied, you have the right to an external review:
- Commercial insurance: Request independent external review through your state insurance department
- Medicare Advantage: Appeal to the Independent Review Entity (IRE), then an Administrative Law Judge (ALJ) if needed
- Original Medicare: Redetermination, then Qualified Independent Contractor (QIC) reconsideration
Sample Appeal Letter Template
[Your Name] [Your Address] [City, State, ZIP] [Date]
[Insurance Company Name] [Appeals Department Address] [City, State, ZIP]
RE: Appeal of Denial — Synvisc-One (hylan G-F 20) Injection Member ID: [Your Member ID] Claim Number: [Claim Number from Denial Letter] Date of Service: [Date of Injection or Planned Date] Patient: [Your Name, DOB]
Dear Appeals Committee:
I am writing to appeal the denial of coverage for Synvisc-One injection for my left/right knee, denied on [denial date] for the reason stated as “[exact denial reason from letter].”
Diagnosis: I have been diagnosed with osteoarthritis of the [left/right] knee (ICD-10: [M17.11 or M17.12]). X-rays dated [date] confirm [describe findings: joint space narrowing, osteophytes, Kellgren-Lawrence grade if known].
Conservative Treatment History:
- Physical therapy: [number] sessions from [start date] to [end date] at [provider]. Result: [describe limited improvement].
- NSAIDs: [medication name] [dosage] taken from [start date] to [end date]. Result: [describe limited relief or side effects].
- Cortisone injection: Administered on [date]. Result: [describe duration of relief and current status].
- Activity modification: [describe efforts such as weight management, assistive devices, exercise changes].
Functional Impact: My knee pain significantly limits my ability to [walk more than X distance, climb stairs, sleep through the night, perform household tasks]. My WOMAC/VAS pain score is [score if available].
Medical Necessity: Synvisc-One is an FDA-approved treatment for knee osteoarthritis. I have exhausted conservative treatment options without adequate relief. My treating physician, [Dr. Name], has determined that Synvisc-One is medically appropriate for my condition. [Reference any supporting clinical studies or guidelines.]
I respectfully request that you reverse this denial and authorize coverage for Synvisc-One injection. Enclosed please find supporting documentation including medical records, imaging reports, and my physician’s letter of medical necessity.
Sincerely, [Your Signature] [Your Printed Name] [Phone Number]
Enclosures: Denial letter, medical records, X-ray reports, physician letter of medical necessity, conservative treatment documentation
CPT and HCPCS Codes for Synvisc-One
Understanding the correct billing codes helps you verify that your claim was submitted properly.
| Code Type | Code | Description |
|---|---|---|
| HCPCS (Product) | J7325 | Hylan G-F 20 (Synvisc/Synvisc-One), per dose |
| CPT (Injection) | 20610 | Arthrocentesis, aspiration and/or injection of major joint (without ultrasound) |
| CPT (Injection w/ imaging) | 20611 | Arthrocentesis with ultrasound guidance |
| ICD-10 (Diagnosis) | M17.0 | Bilateral primary osteoarthritis of knee |
| ICD-10 (Diagnosis) | M17.11 | Primary osteoarthritis, right knee |
| ICD-10 (Diagnosis) | M17.12 | Primary osteoarthritis, left knee |
| Office Visit | 99213/99214 | Established patient office visit (if billed same day) |
Coding Tip
Synvisc-One has its own dedicated J-code (J7325). Some billing errors occur when offices use a generic HA code instead. Verify that J7325 appears on your claim. The product is billed per dose, and Synvisc-One is a single 6 mL dose (48 mg hylan G-F 20).
Synvisc-One Specific Coverage Facts
About Synvisc-One
- Manufacturer: Sanofi (previously Genzyme)
- Active ingredient: Hylan G-F 20 (chemically cross-linked hyaluronan)
- Molecular weight: High (6 million Daltons)
- Injection schedule: Single injection (6 mL)
- FDA approved: Yes, for knee osteoarthritis
- Derived from: Rooster comb (avian-sourced)
Medicare Coverage
Original Medicare Part B covers Synvisc-One for knee osteoarthritis under the same guidelines as other FDA-approved HA products. Patients typically pay 20% coinsurance after the Part B deductible ($257 in 2026). Prior authorization is generally not required under Original Medicare, but Medicare Advantage plans may require it.
Commercial Insurance Coverage
Coverage varies widely. Many commercial plans cover Synvisc-One but require:
- Prior authorization
- Step therapy (typically cortisone injection first)
- Documentation of 3+ months of conservative treatment failure
- Some plans have preferred HA products and may require a formulary exception for Synvisc-One specifically
Common LCD Requirements
Local Coverage Determinations for viscosupplementation typically require:
- Radiographic evidence of osteoarthritis
- Failure of conservative therapy for at least 3 months
- Minimum 6-month interval between injection series
- Treatment limited to the knee joint (coverage for other joints varies)
Tips to Prevent Future Denials
- Document every conservative treatment attempt with specific dates, durations, and outcomes in your medical record before requesting HA injections
- Get prior authorization before scheduling your injection, even if you think it is not required — call your plan to verify
- Use correct diagnosis codes: M17.11 (right knee), M17.12 (left knee), or M17.0 (bilateral)
- Verify the J-code: Ensure J7325 is used for Synvisc-One specifically
- Request imaging guidance documentation if your provider uses ultrasound or fluoroscopy (code 20611 instead of 20610)
- Keep records of prior injection success: If Synvisc-One worked before, document the duration of relief to support retreatment requests
- Ask your provider about avian allergy screening: Since Synvisc-One is avian-sourced, document that you have no known allergy to poultry, feathers, or egg products
Frequently Asked Questions
How long does a Synvisc-One appeal take?
Most insurance plans decide internal appeals within 30 days. Medicare Advantage plans have a 30-day standard timeline and a 72-hour expedited timeline. External reviews typically take an additional 30-60 days. From start to finish, expect 4-12 weeks for the full appeal process.
What is the success rate for Synvisc-One appeals?
While specific success rates vary by insurer, appeals that include complete documentation, a strong letter of medical necessity, and evidence of conservative treatment failure have a reasonable chance of success. Studies on medical necessity appeals generally show overturn rates of 40-60% when properly documented.
Can my doctor help with the appeal?
Yes, and they should. A letter of medical necessity from your treating physician is one of the most important parts of your appeal. Ask your doctor to write a detailed letter explaining why Synvisc-One is medically appropriate for your specific situation and how you meet the plan’s coverage criteria.
What if my second appeal is denied?
If your internal appeal is denied, you have the right to an independent external review. For commercial insurance, contact your state insurance department. For Medicare Advantage, the case goes to an Independent Review Entity. External reviewers overturn insurer denials in a significant percentage of cases, so it is worth pursuing if you believe the denial is wrong.
Is Synvisc-One more likely to be denied than other HA brands?
Synvisc-One is sometimes denied at a slightly higher rate than lower-cost HA products because some plans have preferred product lists. If your plan prefers a different brand, your provider can either request a formulary exception or consider an alternative HA product that may be more easily approved.